Literature DB >> 3593899

Pharmacokinetics of dexamethasone and its phosphate ester.

P Rohdewald, H Möllmann, J Barth, J Rehder, H Derendorf.   

Abstract

Dexamethasone in form of its phosphate was given intravenously in two different doses (1.5 mg kg-1 and 15 mg). Plasma levels of the ester and dexamethasone were measured and pharmacokinetic parameters were calculated. The results indicate no dose-dependency of the pharmacokinetic parameters in the investigated range for dexamethasone. Conversion from the prodrug to the active form was rapid; maximum dexamethasone plasma concentrations were reached after 10 min. The results were verified by dexamethasone level monitoring in patients after chronic dosing. Predicted and achieved steady state levels agreed well.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3593899     DOI: 10.1002/bdd.2510080302

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  21 in total

Review 1.  Pharmacokinetic optimisation of antiemetic therapy.

Authors:  M Campbell; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 2.  Prodrugs for the improvement of drug absorption via different routes of administration.

Authors:  L P Balant; E Doelker; P Buri
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

3.  The pharmacokinetics of low-dose dexamethasone in congenital adrenal hyperplasia.

Authors:  M C Young; N Cook; G F Read; I A Hughes
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Dexamethasone megadoses stabilize rat liver lysosomal membranes by non-genomic and genomic effects.

Authors:  B Hinz; R Hirschelmann
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

5.  Ocular Drug Distribution and Safety of a Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in Rabbit.

Authors:  Kongnara Papangkorn; John W Higuchi; Balbir Brar; William I Higuchi
Journal:  J Ocul Pharmacol Ther       Date:  2018-02-12       Impact factor: 2.671

6.  In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery.

Authors:  C S Leopold; D R Friend
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

7.  Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose.

Authors:  N A Al Katheeri; I A Wasfi; M Lambert; A Saeed
Journal:  Vet Res Commun       Date:  2004-08       Impact factor: 2.459

Review 8.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

9.  Absorption rate limit considerations for oral phosphate prodrugs.

Authors:  Tycho Heimbach; Doo-Man Oh; Lilian Y Li; Markus Forsberg; Jouko Savolainen; Jukka Leppänen; Yasushi Matsunaga; Gordon Flynn; David Fleisher
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

10.  The in vitro enzymic labilities of chemically distinct phosphomonoester prodrugs.

Authors:  A S Kearney; V J Stella
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.